Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Other Operating Expenses (2016 - 2025)

Ani Pharmaceuticals' Other Operating Expenses history spans 16 years, with the latest figure at $117.2 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses changed N/A year-over-year to $117.2 million; the TTM value through Dec 2025 reached $300.0 million, up 42.17%, while the annual FY2025 figure was -$382000.0, 107.14% down from the prior year.
  • Other Operating Expenses for Q4 2025 was $117.2 million at Ani Pharmaceuticals, up from -$295000.0 in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $117.2 million in Q4 2025 and bottomed at -$8.4 million in Q2 2021.
  • The 5-year median for Other Operating Expenses is $58.3 million (2023), against an average of $54.6 million.
  • The largest annual shift saw Other Operating Expenses tumbled 124.47% in 2021 before it surged 672.32% in 2022.
  • A 5-year view of Other Operating Expenses shows it stood at -$350000.0 in 2021, then skyrocketed by 13835.71% to $48.1 million in 2022, then surged by 46.85% to $70.6 million in 2023, then grew by 12.82% to $79.6 million in 2024, then skyrocketed by 47.2% to $117.2 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Other Operating Expenses are $117.2 million (Q4 2025), -$295000.0 (Q3 2025), and $99.2 million (Q2 2025).